ArticleEndocrine2026
Close access to health care as a bridge overcoming disparities in thyroid cancer.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionStudies occasionally demonstrate various ethnic disparities regarding differentiated thyroid cancer (DTC) characteristics and outcomes. The impact of public health care and close access to care has been studied scarcely. With a unique minority group within the hospital region, this case control study aims to investigate this further.
methodsA retrospective cohort study of patients with DTC diagnosis who followed-up at a tertiary medical center between 2013 and 2024. The patients were categorized into Minority (study group) or non-minority (control group) and were reviewed for DTC characteristics at presentation and outcomes including histopathology, risk of structural disease recurrence, response to initial treatment, and mortality and risk group according to the 2015 ATA guidelines [1].
resultsA total of 316 patients were included, of whom 100 (31.6%) constituted the minority group. Two hundred forty-two patients (77%) were females. The minority group was diagnosed at a younger age compared to non-minority group (41 ± 15 vs. 53 ± 15 years, p < 0.001) and had higher rates of female patients (82% vs. 74%, p = 0.12, respectively). The median follow-up of the cohort was 4.41 (2.25–7.21) years. The minority cohort presented with significantly larger tumors (median 20 mm vs. 15 mm, p = 0.042) and a significantly higher prevalence of multifocality (46% vs. 31%, p = 0.03) compared to the non-minority cohort. Conversely, the rate of extrathyroidal extension (ETE) was lower in the minority cohort, although this did not reach statistical significance (21% vs. 32%, p = 0.10, respectively). DTC characteristics did not demonstrate significant differences regarding LN or distant metastasis. While the extent of surgery, ATA risk classification and response to initial therapy were comparable between the groups, the minority cohort required significantly more additional post-operative interventions (20% vs. 11%, p = 0.039). During the study period, 21 (6.6%) patients died, including 6 (1.9%) disease-specific deaths, with no between-group differences in all-cause or disease-specific mortality.
conclusionsOur findings suggest that a good access to non-insurance based, public healthcare may reduce thyroid cancer disparities, which was reported repeatedly up to date. Health system structure and language barriers may play a role in disparities attributed to ethnicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.